| Metric | Value (₹ Cr) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 858.41 | 102.5% | 119.7% |
| Total Income | 872.39 | 104.7% | 119.9% |
| Expenditure | 758.06 | 90.8% | 95.3% |
| PBT | 73.07 | 169.0% | 802.1% |
| Net Profit | 48.52 | 147.6% | 648.8% |
| OPM | 15.65% | 2.92pp | 23.24pp |
| NPM | 5.56% | 0.96pp | 3.93pp |
| EPS | 0.89 | 50.9% | 535.7% |
Viyash Scientific Ltd: Q3 FY26 Revenues Up 10.9%, EBITDA* Surges 64.4%, PAT Increases 15.5%
06 Feb 2026 · 6 Feb, 2:02 am
Summary
Viyash Scientific Ltd, a leading integrated pharmaceutical company, has announced its financial results for the quarter ended December 31, 2025. This is the first quarter where the results of the merged entity are being presented on a combined basis. The company reported a 10.9% increase in revenues, a 64.4% surge in EBITDA, and a 15.5% increase in PAT for Q3 FY26.
Key Highlights
- 1
Revenues at ¥ 8584 Million up by 10.9%
- 2
EBITDA* at ¥ 1854 Million up 64.4 %
- 3
9 Month FY26 — Revenues at ¥ 25004 Million up by 11.9%
- 4
EBITDA* at ¥ 5,024 Million up 58 %
- 5
Q3 FY 26 PAT up 15.5 % (including exceptional merger related costs)
- 6
9 Month FY 26 PAT up by 230%
- 7
Pre closure of high-cost Debt. Net Debt / EBITDA at 0.38 x
Management Comments
Dr Hari Babu Bodepudi
Managing Director and Group CEO
We mark a significant milestone today, announcing results of the merged entity for first time. The results of Q3FY25-26 are an indication of the actions we have taken and the momentum we have built across the last few quarters, working as one team. Revenue, margins, profitability all have continued to show strong growth on the back of new product introductions, cost improvement and synergies across our business units. We have a strong balance sheet and market position and are geared up for capturing the market opportunity in the next 3-5 years. The merger is starting to generate benefits across R&D, manufacturing and front-end, all of which make us very excited for the journey ahead.
Informational and educational content only. Not investment advice.